ClinicalTrials.gg
TerminatedNCT03419403Updated Apr 14, 2021Results posted

UNITE Study: Understanding New Interventions With GBM ThErapy

A Phase 3 interventional study of Steroid eye drops and Vasoconstrictor eye drops in Glioblastoma Multiforme, sponsored by AbbVie. Terminated at 22 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 11 studies in Glioblastoma by AbbVie — none open to participants now, none under way, none of them phase 3. Glioblastoma · AbbVie.

Enrollment
8th of 10
40 · median 58
Started
2018
the only one that year
Phase 3
2 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Glioblastoma by AbbVie, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2018, is one of 2 in phase 3, and was the 11th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

None of the 11 studies in Glioblastoma by AbbVie is open now. The open studies under Glioblastoma, anywhere →

Who these studies take

Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Glioblastoma by AbbVie as a file.
02

Study summary

The objective of this study was to evaluate the effect of several ophthalmologic prophylactic treatment strategies for the management of ocular side effects (OSEs) in participants with epidermal growth factor receptor (EGFR)-amplified glioblastoma (GBM) who were being treated with depatuxizumab mafodotin (ABT-414).

Read the detailed description

This Phase 3b open-label, randomized, exploratory study included 2 phases during the treatment period: chemoradiation therapy (radiation plus temozolomide [RT/TMZ]) and adjuvant therapy (TMZ). All participants received depatuxizumab mafodotin during both phases of the treatment period plus 1 of 3 prophylactic ophthalmologic treatments (standard steroids; standard steroids with vasoconstrictors and cold compress; and enhanced steroids with vasoconstrictors and cold compress. The study comprised a screening period of up to 7 weeks after surgery, a 6-week concomitant Chemoradiation Phase, an Adjuvant Phase beginning approximately 4 weeks after completion of chemoradiation, and a Follow-Up Phase.

03

Conditions studied

  • Glioblastoma Multiforme

Keywords

  • Glioblastoma Multiforme (GBM)
  • Cancer
  • Chemoradiation therapy
  • Epidermal growth factor receptor-amplified glioblastoma
  • Radiation
  • Temozolomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed glioblastoma (GBM) proven, World Health Organization (WHO) grade IV GBM or WHO grade IV gliosarcoma
  • Tumors must demonstrate epidermal growth factor receptor (EGFR) amplification
  • Tumors must be supratentorial in location
  • Participant must have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage
  • Participant has a performance status (KPS) of 70 or higher
  • Participant has adequate bone marrow, renal, and hepatic function
  • without evidence of acute cardiac ischemia ≤ 21 days prior to randomization
  • Participant has a of ≥ 3 months

Exclusion criteria

Exclusion Criteria:

  • Participant has received prior chemotherapy or radiotherapy for cancer of the head and neck region
  • Participant has received prior treatment with Gliadel wafers or any other intratumoral or intracavitary treatment
  • Participant has to any component of temozolomide or dacarbazine
  • Participant has received anti-cancer therapy (including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any therapy) within 5 years of Study Day 1
  • Participant has uncontrolled condition(s) as described in the protocol
  • Participant has any medical condition which in the opinion of the investigator places the participant at an unacceptably high risk for toxicities
  • Participant has had another active within the past 3 years except for any cancer considered cured or non-melanoma carcinoma of the skin
  • Participant has a history of herpetic keratitis
  • Participant is not suitable for receiving ocular with conditions as described in the protocol
  • Participant has had laser-assisted in situ keratomileusis (LASIK) procedure within the last 1 year or cataract surgery within the last 3 months
  • Participant has a visual condition that compromises the ability to accurately measure visual acuity or assess visual activities of daily living (vADLs)
  • Participant has virus or virus infection
  • Participant not receiving treatment with highly active antiretroviral therapy (HAART) when positive for (HIV)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Standard Steroids

    Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days

    Drug: Steroid eye drops · Drug: Depatuxizumab mafodotin · Drug: Temozolomide · Radiation: Radiation

  • Experimental
    Standard Steroids + Vasoconstrictor + Cold Compress

    Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).

    Drug: Steroid eye drops · Drug: Vasoconstrictor eye drops · Other: Cold compress · Drug: Depatuxizumab mafodotin · Drug: Temozolomide · Radiation: Radiation

  • Experimental
    Enhanced Steroids + Vasoconstrictor + Cold Compress

    Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).

    Drug: Steroid eye drops · Drug: Vasoconstrictor eye drops · Other: Cold compress · Drug: Ophthalmic steroid ointment · Drug: Depatuxizumab mafodotin · Drug: Temozolomide · Radiation: Radiation

Interventions

  • DrugSteroidsStudies of SteroidsSteroids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Solution, eye drop

  • DrugVasoconstrictor eye drops

    Solution, eye drop

  • OtherCold compress

    Cold compress

  • DrugSteroidsStudies of SteroidsSteroids pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ointment

  • During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.

    Also known as: ABT-414

  • Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.

  • RadiationRadiation

    Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management

    Inadequate control of ocular side effects (OSE) was defined as either a ≥ 3-line decline from baseline (≥ +0.3 on LogMAR scale) in visual acuity (with baseline correction determined at the screening ophthalmology visit)) or ≥ Grade 3 OSE severity on the Corneal Epithelial Adverse Event (CEAE) scale.

    Time frame: Within 8 weeks after the initial dose of depatuxizumab mafodotin

Secondary outcomes

  1. Maximum Change From Baseline on the Logarithm of the Minimum Angle of Resolution (LogMAR) Scale

    The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment. The baseline observation is defined as the last non-missing measurement collected prior to the first dose of depatuxizumab mafodotin.

    Time frame: Within 8 weeks after the initial dose of depatuxizumab mafodotin

  2. Time to Bandage Contact Lens (BCL) Intervention

    The time to initiation of bandage contact lenses for those participants who required intervention due to inadequate control of ocular side effects (OSE) was calculated.

    Time frame: Up to 9 months after the first dose of depatuxizumab mafodotin

  3. Number of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE)

    Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs.

    Time frame: From the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks

  4. Cumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment

    The cumulative dose of depatuxizumab mafodotin administered was tabulated.

    Time frame: Up to 9 months

  5. Treatment-Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit

    The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).

    Time frame: Up to 47 weeks

  6. Change From Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale After Bandage Contact Lens (BCL) Intervention

    The change on the LogMAR Scale from last assessment prior to BCL intervention to 2 weeks after BCL intervention was calculated. The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.

    Time frame: From the last assessment prior to BCL intervention to 2 weeks after BCL intervention

  7. Percentage of Participants That Recovered to <3-line Decline From Baseline (≤ +0.3 LogMAR) in Visual Acuity After Bandage Contact Lens (BCL) Intervention

    Recovery was defined as return to \<3-line decline from baseline (≤ +0.3 LogMAR) in visual acuity after BCL intervention.

    Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention

  8. Number of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention

    Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs after BCL intervention.

    Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention, up to 38 weeks

  9. Time to Restart Depatuxizumab Mafodotin if Interrupted Due to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention

    The time to restart depatuxizumab mafodotin treatment if it was interrupted due to ocular side effects after BCL Intervention was tabulated.

    Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention

  10. Treatment Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit After Bandage Contact Lens (BCL) Intervention

    The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).

    Time frame: From the last assessment prior to BCL intervention to the end of BCL intervention, up to 38 weeks

  11. Time to Ocular Side Effect (OSE) Symptom Resolution After Drug Discontinuation (Reversibility)

    The time from discontinuation of depatuxizumab mafodotin to OSE symptom resolution (reversibility) was to be recorded.

    Time frame: From the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks

  12. Time to Re-initiation of Depatuxizumab Mafodotin After Dose Interruption

    The time from dose interruption until re-initiation or permanent discontinuation of depatuxizumab mafodotin was to be recorded.

    Time frame: Up to 9 months

07

Results

Posted Apr 14, 2021

Participant flow

Participant flow — Overall Study
MilestoneStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold CompressUntreated Participants
Started1412122
Completed2300
Not completed129122
Withdrew: Withdrawal by subject5251
Withdrew: Progressive disease (per protocol)0220
Withdrew: Other, not specified6451
Withdrew: Left study due to covid-19 restrictions1100

Outcome measures

PrimaryPercentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management

Inadequate control of ocular side effects (OSE) was defined as either a ≥ 3-line decline from baseline (≥ +0.3 on LogMAR scale) in visual acuity (with baseline correction determined at the screening ophthalmology visit)) or ≥ Grade 3 OSE severity on the Corneal Epithelial Adverse Event (CEAE) scale.

Time frame:
Within 8 weeks after the initial dose of depatuxizumab mafodotin
Reported as:
Number · percentage of participants
Percentage of Participants Who Required a Change in Ocular Side Effect (OSE) Management
percentage of participantsStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Bilateral vision50.027.341.7
Vision in worst eye64.372.750.0
SecondaryMaximum Change From Baseline on the Logarithm of the Minimum Angle of Resolution (LogMAR) Scale

The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment. The baseline observation is defined as the last non-missing measurement collected prior to the first dose of depatuxizumab mafodotin.

Time frame:
Within 8 weeks after the initial dose of depatuxizumab mafodotin
Reported as:
Mean · units on a scale
Maximum Change From Baseline on the Logarithm of the Minimum Angle of Resolution (LogMAR) Scale
units on a scaleStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Bilateral vision0.353 ± 0.18880.402 ± 0.19850.272 ± 0.3888
Vision in worst eye0.482 ± 0.20280.528 ± 0.30730.430 ± 0.5120
SecondaryTime to Bandage Contact Lens (BCL) Intervention

The time to initiation of bandage contact lenses for those participants who required intervention due to inadequate control of ocular side effects (OSE) was calculated.

Time frame:
Up to 9 months after the first dose of depatuxizumab mafodotin
Reported as:
Median · months
Time to Bandage Contact Lens (BCL) Intervention
monthsStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Time to Bandage Contact Lens (BCL) InterventionNA (1.1 to NA)3.6 (1.1 to NA)2.1 (1.1 to NA)
SecondaryNumber of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE)

Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs.

Time frame:
From the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks
Reported as:
Count of participants · Participants
Number of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE)
ParticipantsStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Number of Participants With Depatuxizumab Mafodotin Dose Modifications Due to Ocular Side Effects (OSE)232
SecondaryCumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment

The cumulative dose of depatuxizumab mafodotin administered was tabulated.

Time frame:
Up to 9 months
Reported as:
Mean · mg/kg
Cumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment
mg/kgStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Cumulative Dose of Depatuxizumab Mafodotin Received During Chemoradiation and During Adjuvant Treatment8.5 ± 5.8610.5 ± 7.357.0 ± 3.67
SecondaryTreatment-Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit

The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).

Time frame:
Up to 47 weeks
Reported as:
Count of participants · Participants
Treatment-Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit
ParticipantsStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Week 1: Grade 01085
Week 1: Grade 1131
Week 3: Grade 0457
Week 3: Grade 11063
Week 3: Grade 2001
Week 5: Grade 0102
Week 5: Grade 1756
Week 5: Grade 2132
Week 5: Grade 3422
Week 7: Grade 0002
Week 7: Grade 1340
Week 7: Grade 2465
Week 7: Grade 3202
Week 9: Grade 0101
Week 9: Grade 1120
Week 9: Grade 2354
Week 9: Grade 3201
Week 11: Grade 0001
Week 11: Grade 1210
Week 11: Grade 2203
Week 11: Grade 3101
Week 11: Grade 4100
Week 13: Grade 1101
Adj Week 1: Grade 0010
Adj Week 1: Grade 1132
Adj Week 1: Grade 2322
Adj Week 1: Grade 3100
Adj Week 5: Grade 0022
Adj Week 5: Grade 1130
Adj Week 5: Grade 2401
Adj Week 5: Grade 3110
Adj Week 9: Grade 0010
Adj Week 9: Grade 1021
Adj Week 9: Grade 2222
Adj Week 9: Grade 3110
Adj Week 13: Grade 0010
Adj Week 13: Grade 1020
Adj Week 13: Grade 2222
Adj Week 13: Grade 3100
Adj Week 17: Grade 0001
Adj Week 17: Grade 1010
Adj Week 17: Grade 2230
Adj Week 21: Grade 1001
Adj Week 21: Grade 2230
Adj Week 25: Grade 1020
Adj Week 25: Grade 2110
Adj Week 29: Grade 2100
Adj Week 29: Grade 4010
SecondaryChange From Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale After Bandage Contact Lens (BCL) Intervention

The change on the LogMAR Scale from last assessment prior to BCL intervention to 2 weeks after BCL intervention was calculated. The LogMAR scale measures visual acuity on a continuous scale, with a LogMAR value of 0 equivalent to 20/20 visual acuity. Normal vision is considered to be from -0.2 - 0.1; higher values indicate visual impairment.

Time frame:
From the last assessment prior to BCL intervention to 2 weeks after BCL intervention
Reported as:
Mean · units on a scale
Change From Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale After Bandage Contact Lens (BCL) Intervention
units on a scaleStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Within 8 weeks of first dose: Bilateral vision0.325 ± 0.12480.13 ± 0.0990.54 ± 0.1442
Within 8 weeks of first dose: Vision in worst eye0.435 ± 0.05740.52 ± 0.31110.867 ± 0.2914
Within 8 weeks of first adjuvant dose: Bilateral vision-0.10.41 ± 0.2404—
Within 8 weeks of first adjuvant dose: Vision in worst eye-0.10.33 ± 0.0141—
SecondaryPercentage of Participants That Recovered to <3-line Decline From Baseline (≤ +0.3 LogMAR) in Visual Acuity After Bandage Contact Lens (BCL) Intervention

Recovery was defined as return to \<3-line decline from baseline (≤ +0.3 LogMAR) in visual acuity after BCL intervention.

Time frame:
From the last assessment prior to BCL intervention to the end of BCL intervention

No measurements were reported for this outcome.

SecondaryNumber of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention

Dose modifications included depatuxizumab mafodotin withdrawal, interruption, and reductions in dose initiated due to OSEs after BCL intervention.

Time frame:
From the last assessment prior to BCL intervention to the end of BCL intervention, up to 38 weeks
Reported as:
Number · participants
Number of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention
participantsStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Number of Participants With Depatuxizumab Mafodotin Dose Modifications to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention210
SecondaryTime to Restart Depatuxizumab Mafodotin if Interrupted Due to Ocular Side Effects After Bandage Contact Lens (BCL) Intervention

The time to restart depatuxizumab mafodotin treatment if it was interrupted due to ocular side effects after BCL Intervention was tabulated.

Time frame:
From the last assessment prior to BCL intervention to the end of BCL intervention

No measurements were reported for this outcome.

SecondaryTreatment Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit After Bandage Contact Lens (BCL) Intervention

The corneal epithelial adverse event (CEAE) rating scale is designed to record symptoms associated with corneal epitheliopathy caused by antibody-drug conjugates and to grade the severity of findings. The overall CEAE grade is measured on a scale of 0 to 5, with higher values being more severe, reflecting the impact of corneal abnormalities on visual activities of daily living (ADLs). Additional detailed information is collected for specific domains that are commonly affected, with the following ranges (each in order of increasing severity): ocular discomfort (0 - 4), photophobia (0 - 3), and reading (1 - 3).

Time frame:
From the last assessment prior to BCL intervention to the end of BCL intervention, up to 38 weeks
Reported as:
Count of participants · Participants
Treatment Emergent Corneal Epithelial Adverse Event (CEAE) Grade at Each Visit After Bandage Contact Lens (BCL) Intervention
ParticipantsStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
Week 5: Grade 1200
Week 7: Grade 2110
Week 9: Grade 2111
Week 11: Grade 2002
Week 11: Grade 3100
Week 13: Grade 1100
Adj Week 1: Grade 1001
Adj Week 1: Grade 2001
Adj Week 5: Grade 0011
Adj Week 5: Grade 1010
Adj Week 5: Grade 2101
Adj Week 5: Grade 3100
Adj Week 9: Grade 0010
Adj Week 9: Grade 1001
Adj Week 9: Grade 2001
Adj Week 9: Grade 3100
Adj Week 13: Grade 0020
Adj Week 13: Grade 1010
Adj Week 13: Grade 2101
Adj Week 13: Grade 3100
Adj Week 17: Grade 1010
Adj Week 17: Grade 2110
Adj Week 21: Grade 2210
Adj Week 25: Grade 1010
Adj Week 25: Grade 2100
Adj Week 29: Grade 2100
SecondaryTime to Ocular Side Effect (OSE) Symptom Resolution After Drug Discontinuation (Reversibility)

The time from discontinuation of depatuxizumab mafodotin to OSE symptom resolution (reversibility) was to be recorded.

Time frame:
From the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks

No measurements were reported for this outcome.

SecondaryTime to Re-initiation of Depatuxizumab Mafodotin After Dose Interruption

The time from dose interruption until re-initiation or permanent discontinuation of depatuxizumab mafodotin was to be recorded.

Time frame:
Up to 9 months

No measurements were reported for this outcome.

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 49 days after last depatuxizumab mafodotin administration, up to 47 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard Steroids1/14 (7.1%)6/14 (42.9%)14/14 (100%)
Standard Steroids + Vasoconstrictor + Cold Compress1/12 (8.3%)4/12 (33.3%)12/12 (100%)
Enhanced Steroids + Vasoconstrictor + Cold Compress1/12 (8.3%)4/12 (33.3%)12/12 (100%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
FEBRILE NEUTROPENIABlood and lymphatic system disorders0/141/120/12
THROMBOCYTOPENIABlood and lymphatic system disorders1/141/121/12
ULCERATIVE KERATITISEye disorders0/141/120/12
PYREXIAGeneral disorders1/140/121/12
EYE INFECTIONInfections and infestations0/141/120/12
PNEUMONIAInfections and infestations0/141/120/12
TUMOUR PSEUDOPROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/140/121/12
HEADACHENervous system disorders0/140/121/12
HEMIPARESISNervous system disorders1/141/121/12
SEIZURENervous system disorders1/141/120/12
Most frequent other events
Showing 10 of 120
Most frequent other events
EventStandard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold Compress
FATIGUEGeneral disorders6/149/127/12
NAUSEAGastrointestinal disorders6/146/123/12
THROMBOCYTOPENIABlood and lymphatic system disorders3/145/123/12
ALANINE AMINOTRANSFERASE INCREASEDInvestigations2/145/123/12
ALOPECIASkin and subcutaneous tissue disorders2/142/125/12
CONSTIPATIONGastrointestinal disorders5/144/122/12
VOMITINGGastrointestinal disorders5/141/121/12
HEADACHENervous system disorders5/143/124/12
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations4/142/122/12
LYMPHOCYTE COUNT DECREASEDInvestigations1/140/123/12

Baseline characteristics

Safety population: All randomized participants who received at least 1 dose of depatuxizumab mafodotin

Age, Continuous
Age, Continuous(years)Standard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold CompressTotal
Mean47.6 ± 9.8555.2 ± 10.5357.3 ± 8.6953.1 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)Standard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold CompressTotal
Female3418
Male1181130
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Standard SteroidsStandard Steroids + Vasoconstrictor + Cold CompressEnhanced Steroids + Vasoconstrictor + Cold CompressTotal
White12121236
Black or African American1001
Asian1001
08

Study locations

22 sites
  • Usc /Id# 164235
    Los Angeles, California 90033, United States
  • Moffitt Cancer Center /ID# 164234
    Tampa, Florida 33612-9416, United States
  • Rush University Medical Center /ID# 171003
    Chicago, Illinois 60612, United States
  • Northshore University Health System-Evanston /ID# 164221
    Evanston, Illinois 60201, United States
  • CDH-Delnor Health System /ID# 169909
    Warrenville, Illinois 60555, United States
  • Columbia University Medical Center /ID# 164220
    New York, New York 10032-3729, United States
  • Levine Cancer Ins, Carolina Me /ID# 171271
    Charlotte, North Carolina 28204, United States
  • UT Health Science Ctr-Houston /ID# 164223
    Houston, Texas 77030, United States
  • Baylor Scott & White Medical Center- Temple /ID# 170792
    Temple, Texas 76508-0001, United States
  • Royal North Shore Hospital /ID# 169673
    Saint Leonards, New South Wales 2065, Australia
  • Calvary Mater Newcastle /ID# 169672
    Waratah, New South Wales 2298, Australia
  • Royal Brisbane and Women's Hospital /ID# 169674
    Herston, Queensland 4029, Australia
  • Austin Hospital /ID# 169671
    Heidelberg, Victoria 3084, Australia
  • Universitaetsklinik Heidelberg /ID# 169970
    Heidelberg, Baden-Wuerttemberg 69120, Germany
  • Universitaetsklinikum Leipzig /ID# 169969
    Leipzig, Sachsen 04103, Germany
  • Klinikum Univ. Regensburg /ID# 169963
    Regensburg, 93042, Germany
  • Universitatsklinikum Tubingen /ID# 169965
    Tuebingen, 72076, Germany
  • Vrije Universiteit Medisch Centrum /ID# 170152
    Amsterdam, 1081 HV, Netherlands
  • Universitair Medisch Centrum Utrecht /ID# 170149
    Utrecht, 3584 CX, Netherlands
  • Guy's and St Thomas' NHS Found /ID# 207752
    London, London, City Of SE1 9RT, United Kingdom
  • Queen Elizabeth Hospital - BIRMINGHAM /ID# 200657
    Birmingham, B15 2TH, United Kingdom
  • Castle Hill Hospital /ID# 200662
    Cottingham, HU16 5JQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · www.abbvie.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Sep 2019, 13 months.

Results were first posted in Apr 2021, 1 year 7 months after primary completion. A results delay was requested in Aug 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 5, 2018
StartActual
Jul 30, 2018
Primary completionActual
Sep 5, 2019
CompletionActual
Mar 3, 2020
Results delay requested
Aug 26, 2020
Results first posted
Apr 14, 2021
Last update
Apr 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03419403
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Jul 30, 2018
Primary completion
Sep 5, 2019
Completion
Mar 3, 2020
Results posted
Apr 14, 2021
Last update
Apr 14, 2021

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depatuxizumab mafodotin

Start the discussion